Eltrombopag for the treatment of thrombocytopenia due to low- and intermediate risk myelodysplastic syndromes.

Trial Profile

Eltrombopag for the treatment of thrombocytopenia due to low- and intermediate risk myelodysplastic syndromes.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2017

At a glance

  • Drugs Eltrombopag (Primary)
  • Indications Myelodysplastic syndromes; Thrombocytopenia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EQol-MDS
  • Most Recent Events

    • 08 Dec 2015 Results (n=70) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 22 Aug 2015 Planned number of patients changed from 69 to 171 as reported by European Clinical Trial Database.
    • 15 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top